Tempus AI (NASDAQ:TEM – Get Free Report) and Movano (NASDAQ:MOVE – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, valuation, earnings, profitability, institutional ownership and dividends.
Earnings & Valuation
This table compares Tempus AI and Movano”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $693.40 million | 22.51 | -$705.81 million | ($1.19) | -75.50 |
| Movano | $1.01 million | 4.68 | -$23.73 million | ($40.69) | -0.14 |
Volatility & Risk
Tempus AI has a beta of 4.87, meaning that its stock price is 387% more volatile than the S&P 500. Comparatively, Movano has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
Institutional and Insider Ownership
24.2% of Tempus AI shares are held by institutional investors. Comparatively, 16.6% of Movano shares are held by institutional investors. 26.3% of Tempus AI shares are held by insiders. Comparatively, 21.1% of Movano shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Tempus AI and Movano’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -20.98% | -122.86% | -18.09% |
| Movano | -4,302.13% | -359.83% | -203.15% |
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Tempus AI and Movano, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 1 | 8 | 7 | 0 | 2.38 |
| Movano | 1 | 0 | 0 | 0 | 1.00 |
Tempus AI currently has a consensus target price of $79.38, indicating a potential downside of 11.65%. Given Tempus AI’s stronger consensus rating and higher possible upside, analysts plainly believe Tempus AI is more favorable than Movano.
Summary
Tempus AI beats Movano on 12 of the 14 factors compared between the two stocks.
About Tempus AI
Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.
About Movano
Movano Inc. engages in developing a platform to deliver healthcare solutions at the intersection of medical and consumer devices. The company is involved in the development of Evie Ring, which is a wearable designed specifically for women that combines health and wellness metrics comprises resting heart rate, heart rate variability (HRV), blood oxygen saturation (SpO2), respiration rate, skin temperature variability, period and ovulation tracking, and menstrual symptom tracking, as well as activity profile, including steps, active minutes and calories burned, sleep stages and duration, and mood tracking. It develops System-on-a-Chip (SoC) for blood pressure or continuous glucose monitoring (CGM) systems. The company was formerly known as Maestro Sensors Inc. and changed its name to Movano Inc. in August 2018. Movano Inc. was incorporated in 2018 and is based in Pleasanton, California.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
